Fig. 3
From: NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes
NF1 immunohistochemistry in patient-derived glioblastoma samples. Representative IHC shows loss of NF1 immunostaining in NF1 −/− tumor (patient with neurofibromatosis type 1) with A NFC antibody and C iNF-07E antibody. Representative IHC shows retained NF1 immunostaining in NF1 +/+ tumor with B NFC and D iNF-07E. E Plot of NF1 genomic status and corresponding NF1 IHC scores using two NF1 antibodies. F, G I Bar plots demonstrating no difference in expression of candidate surrogate biomarkers selected a priori—phospho-ERK, phospho-S6, p16, podoplanin (PDPN), ATRX, Ki-67, p53—between tumors with retained and lost NF1 immunostaining